Literature DB >> 15286785

Donor APCs are required for maximal GVHD but not for GVL.

Catherine C Matte1, Jinli Liu, James Cormier, Britt E Anderson, Ioanna Athanasiadis, Dhanpat Jain, Jennifer McNiff, Warren D Shlomchik.   

Abstract

Graft-versus-host disease (GVHD) is a major source of morbidity in allogenic stem cell transplantation. We previously showed that recipient antigen-presenting cells (APCs) are required for CD8-dependent GVHD in a mouse model across only minor histocompatibility antigens (minor H antigens). However, these studies did not address the function of donor-derived APCs after GVHD is initiated. Here we show that GVHD develops in recipients of donor major histocompatibility complex class I-deficient (MHC I(-)) bone marrow. Thus, after initial priming, CD8 cells caused GVHD without a further requirement for hematopoietic APCs, indicating that host APCs are necessary and sufficient for GHVD. Nonetheless, GVHD was less severe in recipients of MHC I(-) bone marrow. Therefore, once initiated, GVHD is intensified by donor-derived cells, most probably donor APCs cross-priming alloreactive CD8 cells. Nevertheless, donor APCs were not required for CD8-mediated graft-versus-leukemia (GVL) against a mouse model of chronic-phase chronic myelogenous leukemia. These studies identify donor APCs as a new target for treating GVHD, which may preserve GVL.

Entities:  

Mesh:

Year:  2004        PMID: 15286785     DOI: 10.1038/nm1089

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  124 in total

1.  Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Authors:  Shoji Asakura; Daigo Hashimoto; Shuichiro Takashima; Haruko Sugiyama; Yoshinobu Maeda; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.

Authors:  Yi-Fen Lu; L Cristina Gavrilescu; Monica Betancur; Katherine Lazarides; Hans Klingemann; Richard A Van Etten
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

Review 3.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

4.  Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease.

Authors:  James S Young; Tao Wu; Yuhong Chen; Dongchang Zhao; Hongjun Liu; Tangsheng Yi; Heather Johnston; Jeremy Racine; Xiaofan Li; Audrey Wang; Ivan Todorov; Defu Zeng
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

Review 5.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

6.  Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity.

Authors:  Bradley W Blaser; Noah R Schwind; Seth Karol; Dennis Chang; Samuel Shin; Sameek Roychowdhury; Brian Becknell; Amy K Ferketich; Donna F Kusewitt; Bruce R Blazar; Michael A Caligiuri
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

7.  Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation.

Authors:  Christoph H Schimmelpfennig; Stephan Schulz; Caroline Arber; Jeanette Baker; Ingo Tarner; Jacqueline McBride; Christopher H Contag; Robert S Negrin
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

8.  Emergent autoimmunity in graft-versus-host disease.

Authors:  Elizabeth Tivol; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

9.  Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens.

Authors:  Dallas B Flies; Tomoe Higuchi; Lieping Chen
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

10.  GCNT1-Mediated O-Glycosylation of the Sialomucin CD43 Is a Sensitive Indicator of Notch Signaling in Activated T Cells.

Authors:  Eric Perkey; Dave Maurice De Sousa; Léolène Carrington; Jooho Chung; Alexander Dils; David Granadier; Ute Koch; Freddy Radtke; Burkhard Ludewig; Bruce R Blazar; Christian W Siebel; Todd V Brennan; Jeffrey Nolz; Nathalie Labrecque; Ivan Maillard
Journal:  J Immunol       Date:  2020-02-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.